07:00 Tue 22 Sep 2020
Immupharma PLC - Repayment of Convertible Security
ImmuPharma plc
("ImmuPharma" or the "Company")
Repayment of Convertible Security
ImmuPharma plc (LSE:IMM) (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, stated in its announcement on
The Company announces that Lind has requested repayment of part of its convertible security. The amount to be repaid in accordance with the terms of the convertible security deed is
L1 has not exercised its right to repayment.
Following the repayment the Company still expects to have sufficient cash resources to fund operations through the end of 2023.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
For further information please contact:
|
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases, anti-infectives, metabolic diseases and cancer. The lead program, Lupuzor™, is a first-in class autophagy immunomodulator which is in Phase III for the treatment of systemic lupus erythematosus (lupus / SLE). Lupus is an autoimmune disease which if left untreated can be fatal. Preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. ImmuPharma and Avion Pharmaceuticals signed on
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE